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Psyllium seedsAbstract GERD, return of stomach contents into the esophagus, is one of the most common gas-
trointestinal disorders in medicine. Its common symptoms are heartburn and acid reflux. Usually,
patients with GERD history develop clinical signs such as heartburn accompanied by functional
constipation. Omeprazole, a proton pump inhibitor (PPIs), is a drug of choice for GERD but all
patients do not respond to the drug and long-term use of these drugs leads to infections. According
to the same physiopathology mechanisms of chronic constipation and GERD, improvement of
functional constipation may be effective in relieving symptoms of GERD. According to the effec-
tiveness of psyllium seeds in chronic constipation symptoms, it is predicted to be effective in treating
GERD in patients with chronic constipation.
 2016 Published by Elsevier Ltd. on behalf of Tehran University of Medical Sciences. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Gastroesophageal reflux disease (GERD) and common
treatment
Gastroesophageal reflux disease (GERD) is one of the most
common diseases of the gastrointestinal system. 7% of thepopulation experiences the disease at least once a day and
44% at least once a month. Its prevalence is increasing in East
Asia and especially in Iran. GERD is defined with the return of
stomach contents into the esophagus which leads to mucosal
damage [1]. Its common symptoms are heartburn and regurgi-
tation [2]. Erosive lesions can lead to ulcers, bleeding and
esophagus carcinoma [3,4]. However, many people experience
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ina and respiratory symptoms are present in some patients
[5,6]. Due to the increasing incidence of esophageal cancer in
Iran in comparison with Western societies, treatment and pre-
vention of its complications have a significant role in reducing
patient’s morbidity and mortality. In many cases, GERD does
not respond well to treatment and is associated with relapses.
Omeprazole is a proton pump inhibitor (PPIs) which is pre-
scribed in different diseases such as GERD, peptic ulcers and
dyspepsia. It is widely used worldwide and is also available
over the counter in many pharmacies. The main action of this
group of drugs (PPIs) is reducing gastric acid production. PPIs
are the most potent inhibitors of acid secretion. Omeprazole
side effects include headaches, dizziness, cough, diarrhea, nau-
sea, vomiting and constipation. Sometimes neuromuscular,
skeletal and dermatologic problems were reported when
omeprazole was used. Omeprazole interferes with the absorp-
tion of vitamin B12 and iron, so supplement therapies are
needed [7–11].
Numbers of these patients also suffered from functional
dyspepsia, irritable bowel syndrome (IBS) and chronic consti-
pation [12]. Accompaniment of GERD in patients with func-
tional dyspepsia is known. Some of these patients are
resistant to treatment with PPIS and despite of proper treat-
ments, they will experience relapses. In these patients, treat-
ment of bowel symptoms is very effective in the treatment of
GERD. This connection is abundantly shown in patients with
IBS [13,14]. However, follow-up and treatment of GERD in
patients with functional chronic constipation has not been
carefully studied [15]. The purpose of this study is introduction
of the most effective treatment of GERD in patients with
chronic constipation which prevents its recurrences.
The hypothesis
Chronic constipation which is a result of a reduction in bowel
motility due to a lack of coordination between nerves and mus-
cles is one of motility disorders of the digestive system.
Chronic constipation overlaps a large group of diseases,
including functional dyspepsia, IBS and GERD [16]. 29% of
patients with functional dyspepsia and 29% of patients with
GERD suffer from chronic constipation [17]. This fact shows
the relationship between these motility disorders. According
to the same physiopathology mechanisms of chronic constipa-
tion and GERD, improvement of intestinal motility disorder
may be effective in relieving symptoms of GERD. It means
that GERD is an extra intestinal symptom of constipation
[18]. Other extra intestinal symptoms of constipation such as
headache and depression necessitate the treatment of constipa-
tion [19,20]. Nowadays most centers are commonly used PPIs
such as omeprazole in the treatment of GERD. However,
about one-third of patients do not respond to PPIs. On the
other hand, long-term use of these drugs can lead to infections
(bacteria growth in the small intestine), malnutrition,
decreased bone minerals and decreased absorption of some
drugs such as clopidogrel [21]. It is better to use active materi-
als which improve the symptoms of constipation in the treat-
ment of GERD.
Plantago plant, belonging to the plantaginaceae family, has
about 250 species. Plantago psyllium is one of the most species
[22]. This plant is distributed in North, North East, West andSouth regions of Iran [23]. Psyllium seeds have been used in
Iranian traditional medicine for many years. They are admin-
istered in the treatment of constipation, diarrhea, IBS and
colon cancer. It can also control the treatment of diabetes,
high cholesterol and obesity. This plant is classified as bulk-
forming laxative. It means mucilage of psyllium seeds in the
presence of water swells and forms a gel layer. Mucilage of this
plant increases the peristaltic movements which higher level of
stool moisture and ultimately affect the volume and frequency
of defecation [24,25].
Due to the effectiveness of psyllium seeds in chronic consti-
pation symptoms, it is expected to be effective in treating
GERD in patients with chronic constipation. According to
the reports, this method of treatment has not been studied.
Evaluation of the hypothesis and experimental data
In this clinical trial study, Patients with GERD history of
3 years who develop clinical signs such as heartburn and regur-
gitation accompanied by functional constipation will be stud-
ied. After doing upper endoscopy, esophagitis in patients will
be graded into A, B, C and D according to Los Angeles clas-
sification. Patients included in this study should have no his-
tory of GI cancers, IBS, endocrine, psychotic, cardiac, liver
and kidney diseases. Also they should not consume the drugs
which caused constipation. The patients are randomly divided
into 2 groups using the computerized methods. In the first
group, omeprazole capsules twice a day, half an hour before
breakfast and dinner, will be prescribed. The second group will
be given psyllium solved in hot tap water one hour before
breakfast and dinner to induce bowel movements and com-
plete sense of defecation. Then GERD clinical symptoms
and relapses in these patients based on SPSS software will be
evaluated. This method can be used to treat the disease and
possibly prevent its relapses.
Discussion
GERD, return of stomach contents into the esophagus, is one
of the most common gastrointestinal disorders in medicine
[26]. According to epidemiological studies conducted in the
context of GERD, its prevalence in Asian countries is less than
Western countries [27]. Approximately 10% of Americans
experience heartburn once a day [21]. Epidemiological studies
also report the high prevalence of the disease in our country
[28]. Gastroesophageal reflux is originated from different phys-
iological defects but in general, three main factors which play
roles in beginning of the disease including, (1) transient relax-
ation of lower esophageal sphincter, (2) reduced pressure on
the lower esophageal sphincter and (3) anatomic defects [21].
GERD signs and symptoms are consisting of heart burn, dys-
phagia, chest pain, acid reflux and dry cough [3,4]. Aging is
one of the most important risk factors which increase the risk
of GERD incidence. It is possibly due to relaxation of lower
esophageal sphincter in adults [29–31]. Some studies intro-
duced obesity as the other major risk factors and smoking as
an independent risk factor of reflux [32–34]. Usually the drugs
used in the treatment of GERD reduce or neutralize stomach
acid. H2 receptor antagonists such as cimetidine, ranitidine
and famotidine are prescribed in mild to moderate GERD.
In severe cases or patients with erosive esophagitis or
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omeprazole, lansoprazole are used. These medications are
not always satisfactory. Almost 30% of people with GERD
do not respond to PPIs [21].
Usually GERD happens with other gastrointestinal motil-
ity disorders such as functional constipation. Probably, treat-
ment of functional constipation can be effective in the
treatment of GERD and prevents its recurrences (Fig. 1).
Treatment of constipation may even remove the resistance of
GERD to common drugs. Functional constipation symptoms
based on international standards including, (a) the number of
defecations less than 3 times a week, (b) Hard stool in at least
25% of defecations, (c) Sensation of incomplete defecations in
at least 25% of defecations, (d) Pushing at defecation in at
least 25% of defecations. At least, 2 symptoms for at least
3 months are indicative of the occurrence of functional consti-
pation [16]. Psyllium seeds are very effective in motility disor-
ders as treating constipation. The seeds are swollen in the
presence of water and are known as effective laxatives. There-
fore, it is predicted that use of psyllium seeds might be a new
therapeutic strategy for GERD patients with functional
constipation.
Conclusion
According to the laxative property of psyllium seeds in the
treatment of functional constipation, it might be a drug of
choice in relieving GERD which might also reduce its recur-
rences. Further clinical trial will be carried out to prove this
hypothesis.
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